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Original Contributions

Xhe Clinical Usefulness of Measuring Apolipoproteins in Diabetic
patients: A Preliminary Report*
J. David Fachnie, MD,+ Janet McGill, MD,* Craig Foreback, PhD,§
and Dorothy M. Kahkonen, MD*
A commercial assay for apolipoproteins A-l and B as well as total cholesterol, triglyceride, and highdensity lipoprotein (HDL) cholesterol was applied to 12-hourfasted serum from 24 insulin-dependent
and 19 noninsulin-dependent diabetic persons. Women with noninsulin-dependent diabetes mellitus
(NIDDM) had the highest levels of total cholesterol and apolipoprotein B. Apolipoprotein B valuesfell
within the normal range in all patients except the NIDDM females, where four of the ten (40%)
samples were elevated. When apolipoprotein B was elevated, total cholesterol was also elevated, over
220 mg/dL. Apolipoprotein A-l values fell within or above the normal range in all subjects, and a
considerable discordance was observed between apolipoprotein A-l elevations and HDL cholesterol
elevations.
The divergence between HDL cholesterol and apolipoprotein A-l supports the altered composition
of HDL in the diabetic persons studied. Further study should elucidate the clinical usefulness of
apolipoprotein measurements in diabetic patients. (Henry FordHosp MedJ 1986;34:113-6)

W

hen a commercial assay for apolipoproteins A-1 and B became available, we wondered how this additional information could be used to evaluate risk for atherosclerosis in our
diabetic patients. In nondiabetic persons, apolipoprotein A-l
was claimed to better discriminate those with and without coronary-artery disease than high-density lipoprotein (HDL) cholesterol (1). However, in persons with noninsulin-dependent
diabetes mellitus (NIDDM), a divergence between apolipoprotein A-l and HDL cholesterol suggested that such comparisons
may yield different results in diabetic subjects (2). Our preliminary experience with measuring apolipoproteins A-l and B in
diabetic patients and relating these measurements to commonly
measured triglyceride, cholesterol, and HDL cholesterol is
described.

Materials and Methods
In our clinic, the 43 ambulatory patients with NIDDM and
IDDM (insulin-dependent diabetes mellitus) who donated 12hour fasted blood specimens had the following characteristics:
1) IDDM female, mean age 30 years, mean B M I (body mass

index) 26.6, N = 9; 2) IDDM male, mean age 30 years, mean
BMI 26.7, N = 15; 3) NIDDM female, mean age 58 years,
mean BMI 33.0, N = 9; 4) NIDDM male, mean age 56 years,
mean BMI 27.6, N = 9; and 5) nondiabetic persons, N = 15.
Pasting serum was assayed for triglyceride, cholesterol, and
HDL cholesterol using standard methods (3-5). Glycosylated
hemoglobin was mn by high pressure liquid chromatography by
American Bio-Science Laboratories (Farmington Hills, MI).
'Apolipoproteins A-l and B were assayed with a commercial assay by ligand combined with nephilometry. In this assay, apo-
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lipoproteins A - l and B in serum react with specific antisera
prepared against purified apolipoproteins A-l and B. The resulting antigen-antibody complex increases the turbidity in the solution. A beam of collimated, monochromatic light from a laser
source is passed through the solution, and the antigen-antibody
complexes produce light scatter. The forward light scatter is
measured quantitatively in relative light scatter units and is proportional to the amount of antigen in the sample (6,7).
The data were subjected to statistical analysis including computation of mean, standard deviation, analysis of variance,
paired comparison for significant results, and correlation coefficients (Pearson Product Moment) (8).
Further evaluation of the data for clinical usefulness was made
by comparing the total semm cholesterol, HDL cholesterol, and
apolipoprotein A-l and B values with available reference ranges.
Total semm cholesterol values were compared to the "moderate
risk" for coronary-artery disease category of the Consensus
Conference on Lowering Blood Cholesterol, ie, 75th to 90th
percentile for the Lipid Research Clinic's Prevalence Study (9).
Levels greater than 220 mg/dL were considered to be elevated.
HDL cholesterol levels were compared with Framingham values
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Fig 1—High-density lipoprotein cholesterol in IDDM and
NIDDM patients. I = IDDM patients and II = NIDDM
patients.
(10). Lower HDL cholesterol was shown to increase theriskfor
coronary-artery disease. Depressed HDL cholesterol was defined as less than 45 mg/dL for males and less than 55 mg/dL for
females. Desired ranges for apolipoproteins were defined by our
clinical laboratory as follows: 35 to 147 mg/dL for apolipoprotein B and 95 to 152 mg/dL for apolipoprotein A-l. Higher levels
of apolipoprotein A-1 and lower levels of apolipoprotein B are
supposedly related to a decreased risk for coronary-artery disease in nondiabetic persons (11-14).

Results
The degree of adiposity, as measured by BMI (kg/m-^) and
analyzed by Student's t-test, was not significantly different between our IDDM and NIDDM subjects of the same sex. The

glycosylated hemoglobin, an index of blood sugar control, also
was not significantly different between groups when subjected
to analysis of variance.
Using analysis of variance, the mean cholesterol and
apolipoprotein B were significantly different, p < 0.05, between diabetic subgroups (Table). A paired comparison for significant results revealed that cholesterol was significantly greater
in NIDDM females than in NIDDM males. Also, apolipoprotein B was significantly greater in NIDDM females than in
NIDDM males, IDDM males, and IDDM females.
Correlation coefficients between commonly measured cholesterol, triglyceride, and HDL cholesterol and the apolipoprotein measures were strongly positive: cholesterol and
apolipoprotein B (0.832), low-density lipoprotein (LDL)
cholesterol and apolipoprotein B (0.650), HDL cholesterol and
apolipoprotein A-l (0.786), and triglyceride and apolipoprotein
B (0.806).
Total semm triglycerides were within the laboratory normal
range (40 to 160 mg/dL) for IDDM males and females. Elevations were observed in four of eight (50%) NIDDM males and
four of seven (57%) NIDDM females. Total semm cholesterol
values were elevated in four of nine (44%) IDDM males, three of
five (80%) IDDM females, two of eight (25%) NIDDM males,
and four of eight (50%) NIDDM females.
HDL cholesterol was low, less than 55 mg/dL, in two of four
(50%) IDDM females and in five of seven (71%) NIDDM
females. HDL cholesterol was low, less than 45 mg/dL, in six of
ten (60%) IDDM males and in four of eight (50%) NIDDM
males (Fig 1).
Apolipoprotein B values fell within the normal range in
almost all subjects except for NIDDM females, where four of
ten (40%) values were elevated over 147 mg/dL. When apolipoprotein B was elevated, total cholesterol was also elevated, over
220 mg/dL.
All apolipoprotein A-l values fell within or above the normal
range (Fig 2). Elevations were observed in 11 of 15 (73%) IDDM
males, three of eight (38%) IDDM females, seven of nine (78%)
NIDDM males, and seven of ten (70%) NIDDM females. An
elevation in apolipoprotein A-l was frequentiy found in the same
subject when HDL cholesterol was not elevated. This discordance was not seen in IDDM females, but was observed in six of

Table
Serum Cholesterol, Ti-iglyceride, HDL Cholesterol, and Apolipoproteins*
Number of Glycosylated
Subjects
Hemoglobin
IDDM Male

Cholesterol

Triglycerides

HDL
Cholesterol

Apolipoproteins
B
A-l

15

10.9 (4)t

199 ± 43

107 ± 68

41.7 ± 6.0

78 ' 3() 155 ± 20

IDDM Female

9

12.2(5)

211 ± 4 6

76 ± 17

62.0 ± 30.0

73 ± 31

NIDDM Male

9

8.8 (4)

189 ± 40

160 ± 104

45.7 ± 17.5 78.5 ± 44

180 ± 34

NIDDM Female

10

10.6(5)

246 ± 311

180 ± 91

42.9 ± 13.7 142* ± 56

166 ± 39

Nondiabetic
sample

l.^

78 ± 23

153 ± 21

35-147

95 •152

Reference
normal ranges

6-8.8

140-220

40-160

45 male
55 female

161 ± 45

*A1I numbers are mean ± I standard deviation in mg/dL except glycosylated hemoglobin, which is a percentage.
tNumber inside parentheses indicates number of subjects.
tp < 0.05. See text for explanation.
IDDM ^ insuhn-dependent diabetes mellitus.
NIDDM = noninsulin-dependent diabetes mellitus.

114

Henry Ford Hosp Med J—Vol 34, No 2, 1986

Measuring ApoIipt)proteins in Diabetics—Fachnie el al

Henry

f

•ne (66%) IDDM males, three offive(60%) NIDDM females,
"jj^ two of six (33%) NIDDM males.
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Discussion
The prevalence of coronary-artery disease is 1.2 to 6.6 times
(ligher in diabetic persons than the general population (15). Accurate determination of risk factors should help the physician to
modify this poor outcome. Unfortunately, diabetes mellitus
modifies the lipid phenotype in rather complex ways. Variables
such as age, sex, type of diabetes mellitus, and state of diabetic
control must be considered. Reference ranges for nondiabetic
nersons may not have the same meaning for diabetic persons.
Our diabetic subgroups did not differ in degree of adiposity or
estimate of diabetes control by glycosylated hemoglobin.
The present study represents a preliminary evaluation of
apolipoproteins A-l and B in our metabolism clinic. The patients selected, although few, were more or less representative of
our population of diabetic patients.
We evaluated our data with regard to three questions: 1) What
is the prevalence of abnormal lipid values in our sample? 2)
What differences exist between NIDDM, IDDM, and gender?
3) What additional information of clinical value is provided by
measurement of apolipoproteins A-l and B?
Many of our diabetic subjects had abnormal lipid values. Triglycerides were elevated in 50%; to 57% of NIDDM subjects.
Cholesterol was elevated in 25%) to 80% of all subjects. Depressed HDL cholesterol occurred in over half of all diabetic
persons studied.
Regarding differences between subgroups, NIDDM females
had elevation in both cholesterol and apolipoprotein B that
reached statistical significance. Apolipoprotein B constitutes
the major protein component of LDL. Elevations of apolipoprotein B are related to the development of coronary-artery disease
in nondiabetic persons (16).
An excellent study by Walden et al, which included a large
number of NIDDM and IDDM males and females compared to
an age, sex, and weight matched control group, reported a similar profile of elevated cholesterol, triglyceride, and depressed
HDL cholesterol in NIDDM females (17). Apolipoproteins were
not available in that study. Our results are consistent with the
view that NIDDM females have a particulariy atherogenic lipid
profile and greater risk for coronary-artery disease (18).
When determining what addirional information of clinical
value was provided by apolipoprotein A-1 and B measurement
when combined with triglycerides, cholesterol, and HDL cholesterol, we found a high correlation coefficient between total
cholesterol and apolipoprotein B. Furthermore, when apolipoprotein B was elevated, cholesterol was also elevated. We
concluded that the apolipoprotein B measures reinforced but did
not supplement the clinical impression available from cholesterol measures alone.
Apolipoprotein A-l is the major protein constituent of HDL.
HDL cholesterol levels are inversely related to the risk for ischemic heart disease. We have previously reported lower HDL
cholesterol levels in diabetic persons with vascular disease (19).
Therefore, we would expect to see depressed HDL cholesterol
levels and correspondingly depressed apolipoprotein A-l in a
sample of putative high-risk diabetic persons. In fact, we ob-
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Fig 2—Apolipoprotein A-l in IDDM and NIDDM patients.
I = IDDM patients and II = NIDDM patients.
served a high correlation between HDL cholesterol and
apolipoprotein A - l . However, the apolipoprotein A-l values
were surprisingly high, while HDL cholesterol levels were normal or depressed. The frequent discordance between these two
values presents a problem that demands further study. For example, we can no longer accept the conclusion that apolipoprotein
A-l is more useful than HDL cholesterol in identifying persons
with coronary-artery disease (1). The conclusion may be premature or may apply only to the nondiabetic patient.
A similar trend of elevated apolipoprotein A-l levels despite
relatively low HDL cholesterol has been previously observed in
NIDDM women (2). An increase in HDL triglyceride without
alteration in HDL particle number was used to explain this divergence. Other authors have also observed a divergence between
HDL cholesterol and apolipoprotein A-l in IDDM patients (20).
We concluded that the divergence between HDL cholesterol and
apolipoprotein A-l supports the concept of an altered composition of HDL in the diabetic persons studied. Further investigation should focus on the composition of HDL and its
relationship to atherosclerosis and other complications of diabetes mellitus.
The available data suggest that the clinical measurement of
apolipoprotein B in diabetic persons will reinforce but not necessarily supplement the impression of coronary-artery disease
risk provided by cholesterol alone. The measurement of
apolipoprotein A - l , as an isolated value, may give a false impression of low risk. Accordingly, we cannot recommend the
routine clinical measurement of apolipoproteins in diabetic persons at this time.
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